Skip to content

Jiangxi Fushine Pharmaceutical Co Ltd Sustainability Reports

The company engages in the research, development, production, and sale of active pharmaceutical ingredients (APIs) and intermediates, primarily focusing on beta-lactamase inhibitors and carbapenem antibiotics.

Sector: Manufacturing

Country: China

Exchange: Shenzhen Stock Exchange

FIGI: BBG006LJ4J14

7 reports from 2021 to 2025